Intellis platform for spinal cord stimulation and peripheral nerve stimulation receives CE Mark- Medtronic.

Medtronic plc announced that it received CE (Conformit� Europ�enne) Mark for the Intellis platform for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) as an aid in the management of certain types of chronic pain. Intellis, the world's smallest fully implantable SCS neurostimulator, simplifies and improves the patient experience with improved battery performance that can power the EvolveSM workflow, which standardizes guidance and balances high-dose (HD) and low-dose (LD) SCS therapy settings. The Intellis platform is managed on the Samsung Galaxy Tab S2 tablet interface and can record and track patient activity 24/7. Intellis is now available in Europe and the United States.

One in five adults in Western Europe suffers from chronic pain, a devastating condition with a costly personal and societal impact. Chronic pain can negatively impact all aspects of a person's life - relationships, work productivity and activities of daily living, yet it remains under-recognized and undertreated.

Published studies have shown that when used by carefully selected patients with chronic pain, SCS may provide effective long-term pain relief, improved quality of life and pain-related disability, and may reduce the need for pain medications. Similarly, PNS may also provide back pain relief, improvement in back pain-related disability, and reduce the need for pain medications. The potential benefits of neurostimulation are critical given the public health issue of prescription pain medication abuse. Earlier intervention with SCS has been shown to improve treatment outcomes and SCS is widely reimbursed and recommended by European governments. Current European guidelines support the use of SCS; failed back surgery syndrome is the primary indication recommended by European governments.